HAEMALOGIX
Haemalogix focuses on the development and commercialization of novel immuno-oncology and immune-therapies.HaemaLogiX acquired the business and assets of Immune System Therapeutics Ltd and is embarking on a program of several inter-related projects that will validate antigen targets and products. Two novel drug targets - Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA), have been identified on the surface of human blood cancer and autoimmune cells. These targets are highly specific... to abnormal B-cells and have been identified in blood cancers such as multiple myeloma (MM), lymphoma and Waldenstroms macroglobulinemia. Our program will rationally review and pursue opportunities that will deliver a positive proof of the clinical and financial viability of our assets. These opportunities include: validation of antibodies and CAR-T cells; proof of concept for both Kappa and Lambda antigens; and a good understanding of their clinical utility in treating the selected patient populations In pursuing these projects we wish to deliver significant and risk mitigated medium term returns to our investors.
HAEMALOGIX
Industry:
Biotechnology Health Care Life Science Medical
Address:
Sydney, New South Wales, Australia
Country:
Australia
Website Url:
http://www.haemalogix.com
Total Employee:
1+
Status:
Active
Contact:
+61292094444
Email Addresses:
[email protected]
Total Funding:
10 M AUD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Euro Microsoft Exchange Online GStatic Google Static Content Sectigo SSL Sectigo Domain SSL
Similar Organizations
Arctic Vision
Arctic Vision is focused on the development and commercialization of innovative ophthalmology therapies.
iRepertoire
iRepertoire is to develop and commercialize immune repertoire sequencing technology and products.
myNEO
myNEO engages in the research, development, and optimization of the clinical exploitability of personalized cancer immunotherapy.
MYOR
MYOR uses skin-surface noninvasive monitoring technologies to adjust nutrition and enable health.
Pharmaceutical Biotechnology
Pharmaceutical Biotechnology focuses on the development and implementation of new biotech projects with high market potential.
Proteona
Proteona develops a genomic and proteomic analysis platform designed for immuno-oncology and immune profiling applications.
Reset Pharmaceuticals
Reset Pharma is a biotechnology company that focuses on the development and commercialization of novel psychedelic treatments.
ScalmiBio
ScalmiBio minimizes side-effects of oncology and immuno-oncology antibody therapeutics.
Senseonics
Senseonics is a medical device startup company that focuses on the design, development, and commercialization of glucose monitoring systems.
Current Employees Featured
Founder
Investors List
Platinum Asset Management
Platinum Asset Management investment in Venture Round - Haemalogix
Official Site Inspections
http://www.haemalogix.com
- Host name: ec2-3-104-128-115.ap-southeast-2.compute.amazonaws.com
- IP address: 3.104.128.115
- Location: Sydney Australia
- Latitude: -33.8591
- Longitude: 151.2002
- Timezone: Australia/Sydney
- Postal: 2000
More informations about "Haemalogix"
HaemaLogiX | Company Overview
HaemaLogiX is a clinical stage Australian biotechnology company, advancing a pipeline of next generation immunotherapies for blood cancers and B-cell disorders. Unlike current therapies, …See details»
Haemalogix - Crunchbase Company Profile & Funding
Haemalogix focuses on the development and commercialization of novel immuno-oncology and immune-therapies.See details»
HaemaLogiX 2025 Company Profile: Valuation, Funding …
Information on valuation, funding, cap tables, investors, and executives for …See details»
HaemaLogiX - Craft
HaemaLogiX has 5 employees at their 1 location. See insights on HaemaLogiX including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
HaemaLogiX Ltd | LinkedIn
HaemaLogiX focus is the development and commercialisation of novel immuno-oncology and immune-therapies. HaemaLogiX is embarking on a program of several inter-related research …See details»
Haemalogix - The Org
Haemalogix focuses on the development and commercialization of novel immuno-oncology and immune-therapies.See details»
HaemaLogiX Pty Ltd. - Drug pipelines, Patents, Clinical trials
Jun 9, 2025 Explore HaemaLogiX Pty Ltd. with its drug pipeline, therapeutic area, technology platform, 8 news, and 1 literature, Disease Domain:Hemic and Lymphatic Diseases ...See details»
Pipeline - Haemalogix
Pipeline HaemaLogiX is engaged in three broad areas of research and development. First, Research & Discovery involves discovering and …See details»
Haemalogix - 2025 Company Profile & Team - Tracxn
Jun 23, 2025 Haemalogix - Developer of immunotherapies for blood cancers and autoimmune diseases. Raised a total funding of $7.47M over 1 round from 3 investors.See details»
HaemaLogiX Ltd - VentureRadar
HaemaLogiX is at the forefront of developing innovative immunotherapies for patients with blood cancers and B-cell disorders. Specializing in monoclonal antibodies, CAR-T cells, and …See details»
HaemaLogiX | Mission & Vision
Our Mission To bring next-generation immunotherapies for multiple myeloma and B cell disorders to market that will transform outcomes by prolonging survival while preserving quality of life for …See details»
Haemalogix - Leadership Team | The Org
The Leadership Team at Haemalogix is responsible for setting the strategic direction of the company, driving innovation in immuno-oncology and immune-therapies, and overseeing …See details»
Info HaemaLogiX - Sydney, New South Wales, Australia - LinkedIn
HaemaLogiX Ltd - development and commercialisation of novel immuno-oncology and immune-therapies · HaemaLogiX focus is the development and commercialisation of novel immuno …See details»
HaemaLogiX | Corporate Governance
At HaemaLogiX, we are committed to maintaining the highest standards of corporate governance to ensure transparency, accountability, and integrity across all aspects of our business. Our …See details»
HaemaLogiX - Startup Galaxy
HaemaLogiX focus is the development and commercialisation of novel immuno-oncology and immune-therapies. HaemaLogiX is embarking on a program of several inter-related research …See details»
Haemalogix - Funding, Financials, Valuation & Investors
Haemalogix focuses on the development and commercialization of novel immuno-oncology and immune-therapies.See details»
HaemaLogix | Board of Directors
Executive Chair Dr John Cullity is Executive Chairman at HaemaLogiX and was a Co-Founder of the Company and has been a Director since the Company's incorporation.See details»
HaemaLogiX Sets the Stage for a $20 Million IPO | Innovation
Apr 7, 2025 HaemaLogiX is preparing for a $20 million IPO in 2025, with groundbreaking innovations like KappaMab and KMA.CAR-T showing promising results in multiple myelomaSee details»
HaemaLogiX | Technology
HaemaLogiX’s immunotherapies bind to unexploited and unique targets (antigens) on the surface of cancerous plasma cells. These antigens are called kappa myeloma antigen (KMA) and …See details»
HaemaLogiX | Latest News
Feb 1, 2024 HaemaLogiX's CMDO, Tertia Dex to speak at the Women in BIO and Health – Industry and Networking Forum HaemaLogiX's CMDO, Tertia Dex will be speaking at the …See details»